The results of this study further support the significance of SGLT-2 inhibitors as a useful treatment choice in patients with T2DM, offering important insights into the preventive benefits of these medications in patients with T2DM at risk of heart failure. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.